| NCT06340360 | A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA) | ACTIVE_NOT_RECRUITING | PHASE2 | 2024-04-02 | 2026-08 | 2025-11 |
| NCT06136741 | A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis | ACTIVE_NOT_RECRUITING | PHASE2 | 2023-11-15 | 2026-12-31 | 2025-05-06 |
| NCT05664217 | NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma | TERMINATED | PHASE2, PHASE3 | 2022-12-23 | 2024-08-16 | 2024-05-22 |
| NCT05565729 | A Phase I Study of LY3471851 in Healthy Participants | COMPLETED | PHASE1 | 2022-10-05 | 2023-02-23 | 2023-02-23 |
| NCT04969861 | BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36) | TERMINATED | PHASE2, PHASE3 | 2022-03-09 | 2022-04-22 | 2022-04-22 |
| NCT04998487 | A Single-Dose Study of LY3471851 in Healthy Participants | COMPLETED | PHASE1 | 2021-08-16 | 2022-07-06 | 2022-07-06 |
| NCT04677179 | A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC) | TERMINATED | PHASE2 | 2021-03-22 | 2022-08-09 | 2022-08-09 |
| NCT04646044 | A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19 | COMPLETED | PHASE1 | 2020-11-13 | 2021-05-18 | 2021-05-11 |
| NCT04616196 | Study of NKTR 255 in Combination With Cetuximab in Solid Tumors | COMPLETED | PHASE1, PHASE2 | 2020-10-30 | 2023-03-30 | 2023-03-30 |
| NCT04433585 | A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE) | COMPLETED | PHASE2 | 2020-08-19 | 2023-02-16 | 2023-01-10 |
| NCT04410445 | Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence | TERMINATED | PHASE3 | 2020-07-27 | 2022-09-22 | 2022-09-22 |
| NCT04081350 | A Study of LY3471851 in Participants With Eczema | COMPLETED | PHASE1 | 2019-12-04 | 2022-06-24 | 2022-06-24 |
| NCT04119557 | A Study of LY3471851 in Participants With Psoriasis | COMPLETED | PHASE1 | 2019-11-26 | 2021-07-21 | 2021-07-21 |
| NCT04133116 | A Study of LY3471851 in Healthy Participants | COMPLETED | PHASE1 | 2019-10-29 | 2020-03-06 | 2020-03-06 |
| NCT04136756 | NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma | COMPLETED | PHASE1 | 2019-10-07 | 2023-04-24 | 2023-04-24 |
| NCT04955262 | A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab | WITHDRAWN | PHASE1 | 2019-08 | 2022-01 | 2021-06 |
| NCT03785925 | A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer | COMPLETED | PHASE2 | 2019-04-29 | 2022-06-30 | 2022-02-09 |
| NCT03729245 | A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) | TERMINATED | PHASE3 | 2018-12-18 | 2022-10-19 | 2022-01-07 |
| NCT03802227 | A Study Using fMRI Imaging to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy, Non-physically Dependent Recreational Opioid Users. | TERMINATED | PHASE1 | 2018-10-22 | 2020-01-03 | 2019-12-17 |
| NCT03556007 | A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE) | COMPLETED | PHASE1 | 2018-04-18 | 2019-08-29 | 2019-08-29 |
| NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies | TERMINATED | PHASE1, PHASE2 | 2018-03-15 | 2022-05-09 | 2022-05-09 |
| NCT03138889 | Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors | TERMINATED | PHASE1, PHASE2 | 2017-06-09 | 2022-08-24 | 2022-07-05 |
| NCT04380324 | A Study of NKTR-358 (LY3471851) in Healthy Participants | COMPLETED | PHASE1 | 2017-03-19 | 2019-01-20 | 2019-01-20 |
| NCT02983045 | A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors | COMPLETED | PHASE1, PHASE2 | 2016-12-19 | 2022-04-28 | 2022-04-28 |
| NCT02915744 | A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine | COMPLETED | PHASE3 | 2016-11 | 2020-07 | 2020-07 |
| NCT02869295 | A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors | COMPLETED | PHASE1, PHASE2 | 2015-12 | 2018-10-31 | 2018-10-31 |
| NCT02367820 | Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain | COMPLETED | PHASE3 | 2015-04-14 | 2018-01 | 2017-12 |
| NCT02362672 | Efficacy and Safety Study of NKTR-181 in Opioid-Naive Subjects With Low Back Pain | COMPLETED | PHASE3 | 2015-03-11 | 2017-02 | 2016-12 |
| NCT01976143 | A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety | COMPLETED | PHASE1 | 2014-02 | 2016-09 | 2016-06 |
| NCT01991678 | A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol) | COMPLETED | PHASE1 | 2013-11 | 2017-09 | 2017-05 |
| NCT01619839 | A Phase 2 Study To Assess The Efficacy, Tolerability, And Safety OF NKTR-181 In Subjects With Chronic OA Knee Pain | COMPLETED | PHASE2 | 2012-06 | 2013-09 | 2013-08 |
| NCT01492101 | The BEACON Study (Breast Cancer Outcomes With NKTR-102) | COMPLETED | PHASE3 | 2011-12 | 2016-06 | 2016-04 |
| NCT01457118 | An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies | COMPLETED | PHASE2 | 2011-10 | 2017-11 | 2017-08 |
| NCT00856375 | NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer | COMPLETED | PHASE2 | 2008-12 | 2014-12 | 2014-07 |
| NCT00806156 | Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer | COMPLETED | PHASE2 | 2008-10 | 2013-01 | 2012-10 |
| NCT00802945 | Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer | COMPLETED | PHASE2 | 2008-10 | 2012-01 | 2011-10 |
| NCT00598975 | NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b) | COMPLETED | PHASE2 | 2008-02 | 2011-12 | 2009-05 |